CO2017011583A2 - Polipéptidos dirigidos a la fusión de vih - Google Patents

Polipéptidos dirigidos a la fusión de vih

Info

Publication number
CO2017011583A2
CO2017011583A2 CONC2017/0011583A CO2017011583A CO2017011583A2 CO 2017011583 A2 CO2017011583 A2 CO 2017011583A2 CO 2017011583 A CO2017011583 A CO 2017011583A CO 2017011583 A2 CO2017011583 A2 CO 2017011583A2
Authority
CO
Colombia
Prior art keywords
hype
polypeptides
relates
directed polypeptides
fusion
Prior art date
Application number
CONC2017/0011583A
Other languages
English (en)
Inventor
Mark R Krystal
David L Wensel
Jonathan Davis
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of CO2017011583A2 publication Critical patent/CO2017011583A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)

Abstract

La invención se refiere a polipéptidos que comprenden una porción de fijación a CD4, una porción de fijación a gp41, una porción inhibidora peptídica de la fusión de VIH y combinaciones de estas. Más específicamente, la presente invención se refiere a polipéptidos que comprenden una proteína del dominio de soporte a base de fibronectina que se fija a CD4, una proteína del dominio de soporte a base de fibronectina que se fija al dominio N17 de gp41 y un inhibidor peptídico de la fusión de VIH, o combinaciones de estos. La invención también se refiere al uso de las proteínas innovadoras en aplicaciones terapéuticas para tratar el VIH.
CONC2017/0011583A 2015-04-24 2017-11-14 Polipéptidos dirigidos a la fusión de vih CO2017011583A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US201562257474P 2015-11-19 2015-11-19
PCT/US2016/027424 WO2016171980A1 (en) 2015-04-24 2016-04-14 Polypeptides targeting hiv fusion

Publications (1)

Publication Number Publication Date
CO2017011583A2 true CO2017011583A2 (es) 2018-04-19

Family

ID=55809237

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011583A CO2017011583A2 (es) 2015-04-24 2017-11-14 Polipéptidos dirigidos a la fusión de vih

Country Status (25)

Country Link
US (2) US10407490B2 (es)
EP (2) EP3985020A1 (es)
JP (3) JP6894846B2 (es)
KR (1) KR20170138558A (es)
CN (1) CN107922474A (es)
AU (2) AU2016252008B2 (es)
BR (1) BR112017022790A2 (es)
CA (1) CA2983276A1 (es)
CL (1) CL2017002687A1 (es)
CO (1) CO2017011583A2 (es)
CR (1) CR20170482A (es)
DO (1) DOP2017000246A (es)
EA (1) EA035332B1 (es)
ES (1) ES2884267T3 (es)
HK (1) HK1243432A1 (es)
IL (1) IL255122A0 (es)
MA (2) MA56222A (es)
MX (1) MX2017013687A (es)
PE (1) PE20180162A1 (es)
PH (1) PH12017501914A1 (es)
PT (1) PT3286212T (es)
SG (1) SG11201708441RA (es)
TW (1) TW201643185A (es)
UY (1) UY36650A (es)
WO (1) WO2016171980A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
EP3728310A1 (en) 2017-12-18 2020-10-28 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CN108997482A (zh) * 2018-08-09 2018-12-14 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (en) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
AU2022338817A1 (en) * 2021-08-30 2024-03-07 Kanglin Biotechnology (Hangzhou) Co., Ltd. Gene sequence construct for gene therapy for hiv infection

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE69835143T2 (de) 1997-01-21 2007-06-06 The General Hospital Corp., Boston Selektion von proteinen mittels rns-protein fusionen
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU2001277867B2 (en) 2000-07-11 2006-12-07 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN101152574A (zh) * 2002-09-27 2008-04-02 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
ES2466716T3 (es) 2002-11-08 2014-06-11 Ablynx N.V. Anticuerpos de un solo dominio estabilizados
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
CA2710835A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
EP3173424A1 (en) 2008-05-02 2017-05-31 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
DK2558491T3 (en) * 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
BR112012028006A2 (pt) * 2010-05-07 2016-08-02 Hoffmann La Roche método de imuno-histoquímica (ihq), uso de um domínio de ligação, kit e domínio de ligação terapeuticamente ativo
WO2012088006A1 (en) 2010-12-22 2012-06-28 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
CA2834577A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
KR102142385B1 (ko) 2011-09-27 2020-08-10 얀센 바이오테크 인코포레이티드 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드
WO2014120891A2 (en) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CN103333255A (zh) 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Also Published As

Publication number Publication date
AU2016252008A1 (en) 2017-11-09
JP2021035951A (ja) 2021-03-04
CA2983276A1 (en) 2016-10-27
MA56222A (fr) 2022-04-20
MX2017013687A (es) 2018-07-06
EA201792269A1 (ru) 2018-04-30
US20180111980A1 (en) 2018-04-26
ES2884267T3 (es) 2021-12-10
KR20170138558A (ko) 2017-12-15
JP7465378B2 (ja) 2024-04-10
EA035332B1 (ru) 2020-05-28
US11155602B2 (en) 2021-10-26
US20190359688A1 (en) 2019-11-28
EP3286212A1 (en) 2018-02-28
AU2016252008B2 (en) 2019-06-13
AU2019226255A1 (en) 2019-09-26
UY36650A (es) 2016-11-30
WO2016171980A1 (en) 2016-10-27
BR112017022790A2 (pt) 2018-07-17
EP3985020A1 (en) 2022-04-20
IL255122A0 (en) 2017-12-31
PT3286212T (pt) 2021-08-24
JP2023055875A (ja) 2023-04-18
DOP2017000246A (es) 2018-01-31
CL2017002687A1 (es) 2018-04-20
PE20180162A1 (es) 2018-01-18
PH12017501914A1 (en) 2018-03-05
HK1243432A1 (zh) 2018-07-13
SG11201708441RA (en) 2017-11-29
CN107922474A (zh) 2018-04-17
JP2018516247A (ja) 2018-06-21
JP6894846B2 (ja) 2021-06-30
EP3286212B1 (en) 2021-06-02
US10407490B2 (en) 2019-09-10
CR20170482A (es) 2018-03-07
MA41943A (fr) 2018-02-28
TW201643185A (zh) 2016-12-16

Similar Documents

Publication Publication Date Title
CO2017011583A2 (es) Polipéptidos dirigidos a la fusión de vih
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
UY36965A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CL2020003422A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
BR112018012707A2 (pt) inibidores da interação de menin-mll
UY35964A (es) Anticuerpos humanos para pd?1
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
PE20170256A1 (es) Proteinas de union y sus metodos de uso
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
CO2019002482A2 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
UY35407A (es) ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?.
UY37456A (es) Inmunoglobulinas y sus usos
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
CL2017002881A1 (es) Anticuerpos anti-fcrn
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
CL2020002597A1 (es) Métodos para preparar composiciones proteicas estables
MX2016013819A (es) Vacuna profilactica contra el sindrome de caida del huevo (eds).
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION